Home
About
- Our Team
- Careers
News
Contact

Technology
Diagnostics
Therapeutics
- Drug Discovery
- Safer Drugs
Products
- Sales
- Licensing & Distribution
Services
Resources

AmberGen awarded 2-year Phase II SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions

July 2014/in News /by Kenneth Rothschild

Share this entry

https://www.ambergen.com/wp-content/uploads/logo-retina.png 0 0 Kenneth Rothschild https://www.ambergen.com/wp-content/uploads/logo-retina.png Kenneth Rothschild2014-07-27 13:39:312016-11-10 12:44:44AmberGen awarded 2-year Phase II SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions

Menu

Home
About
Technology
Diagnostics
Therapeutics

Products
Services
Resources
News
Contact

Get in Touch

AmberGen, Inc.

313 Pleasant St.

Watertown, MA 02472

(617) 923-9990

info@ambergen.com

Recent News

Recent Posts

AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing March 2018
Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™) February 2018

© 2020 - AmberGen Inc. Website designed in Massachusetts

AmberGen awarded 3-year Phase II SBIR grant from NIH-NIAID for development of... AmberGen and Massachusetts General Hospital (MGH) are awarded US Patent 8,852,956...

Scroll to top